RxDoctor Payments Data

Aisha Taylor, MD

Urogynecology and Reconstructive Pelvic Surgery · Hanover, MDNPI 1336467414

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,000 of the $29,274 with a category attached, or 64.9%. Axonics, Inc. accounts for 93.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $18,947 and has fallen 99.3% since, to $130 in 2025.

$29,274in general payments, 2019–2025

Across 169 payments — averaging $173.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$27K
  • Johnson & Johnson$261
  • AbbVie$225
  • Endo Pharmaceuticals Inc.$177
  • Urovant Sciences Inc$128
  • Boston Scientific$123
  • plus $995 from 23 others
$74,525in research payments, 2019–2025

Across 167 payments — averaging $446.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axonics, Inc.$75K

What the payments were for

  • Consulting fees$19,00065%
  • Speaking & faculty fees$1160%
  • Travel & lodging$7,13124%
  • Food & beverage$3,02810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$9,490
Medicare patients
43
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other urogynecology and reconstructive pelvic surgery in Hanover

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →